Repligen trades at $120.32 per share and has moved almost in lockstep with the market over the last six months. The stock has ...

Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team’s engagement ...

Guggenheim analyst Subbu Nambi maintained a Hold rating on Repligen (RGEN – Research Report) yesterday. The company’s shares closed yesterday ...

Learn more about whether Medpace Holdings, Inc. or Repligen Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN – Free Report) from a sell rating to a hold rating in a research note ...

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the ...

WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role ...